Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ARRB1 | P49407 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL15501048 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2997 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL5183254 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7987114 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10031250 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932349-B2 | 8-carboxamido-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| US-20160075658-A1 | 4-HYDROXYBENZOMORPHANS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150342929-A1 | Mixed ORL1/mu-agonists for the Treatment of Pain | GRUENENTHAL GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20150011768-A1 | 4-HYDROXYBENZOMORPHANS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2015-01-08 | — | — | US | disclosed |
| US-8901148-B2 | Large substituent, non-phenolic opioids and methods of use thereof | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2014-12-02 | — | — | US | disclosed |
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8716306-B2 | Carboxamide bioisosteres of opiates | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140107143-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2014-04-17 | — | — | US | disclosed |
| US-20100130512-A1 | FUSED-RING HETEROCYCLE OPIOIDS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20090048447-A1 | METHOD FOR DECREASING OPIOID METABOLISM | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080233078-A1 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-09-25 | — | — | US | disclosed |
| US-20080233078-A1 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-09-25 | — | — | US | disclosed |
| US-20080226583-A1 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-09-18 | — | — | US | disclosed |
| US-20080226583-A1 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-09-18 | — | — | US | disclosed |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | GRUNENTHAL GMBH (DE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | GRUNENTHAL GMBH (DE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008040481-A1 | MIXED ORL 1/μ AGONISTS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |
| US-20070238748-A1 | Methods for Treating Diseases with 4-Hydroxybenzomorphans | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107143-A1 | QUATERNARY OPIOID CARBOXAMIDES | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20080233078-A1 | THERAPEUTIC POLYESTERS AND POLYAMIDES | NPEPPS, PAICS, PUF60 | OPRM1 3066/4885OPRD1 3052/4885OPRK1 2725/4885 |
| US-20080226583-A1 | THERAPEUTIC POLYESTERS AND POLYAMIDES | NPEPPS, PAICS, PUF60 | OPRM1 3066/4885OPRD1 3052/4885OPRK1 2725/4885 |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20160075658-A1 | 4-HYDROXYBENZOMORPHANS | HTR3C, OPRL1, OPRK1 | OPRM1 4/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20090048447-A1 | METHOD FOR DECREASING OPIOID METABOLISM | OPRM1, OPRK1, CYP3A43 | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
| US-20150011768-A1 | 4-HYDROXYBENZOMORPHANS | HTR3C, OPRL1, OPRK1 | OPRM1 4/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20100130512-A1 | FUSED-RING HETEROCYCLE OPIOIDS | OPRK1, OPRD1, OPRL1 | OPRM1 4/4885OPRD1 2/4885OPRK1 1/4885 |
| US-20070238748-A1 | Methods for Treating Diseases with 4-Hydroxybenzomorphans | TPMT, HTR3C, PYGL | OPRM1 65/4885OPRD1 78/4885OPRK1 11/4885 |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | HRH4, HRH2, HRH3 | OPRM1 8/4885OPRD1 38/4885OPRK1 27/4885 |
| US-20150342929-A1 | Mixed ORL1/mu-agonists for the Treatment of Pain | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.